Artelo Biosciences logo

Artelo BiosciencesNASDAQ: ARTL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 June 2019

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$3.68 M
-88%vs. 3y high
10%vs. sector
-vs. 3y high
-vs. sector
-78%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 22:53:59 GMT
$1.14+$0.05(+4.59%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ARTL Latest News

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
globenewswire.com13 November 2024 Sentiment: POSITIVE

ART26.12, the Company's Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain Studies ART26.12, the Company's Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain Studies

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program
globenewswire.com05 November 2024 Sentiment: POSITIVE

SOLANA BEACH, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that ART26.12, the Company's lead clinical FABP inhibitor, has been accepted into the NIH Helping to End Addiction Long Term (HEAL) Initiative's Preclinical Screening Platform for Pain (PSPP).

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
globenewswire.com13 August 2024 Sentiment: POSITIVE

SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported its financial and operating results for the three months ended June 30, 2024 and provided a business update.

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
globenewswire.com03 July 2024 Sentiment: POSITIVE

Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
GlobeNewsWire19 July 2023 Sentiment: POSITIVE

New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy

Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
GlobeNewsWire07 June 2023 Sentiment: POSITIVE

ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD

What type of business is Artelo Biosciences?

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

What sector is Artelo Biosciences in?

Artelo Biosciences is in the Healthcare sector

What industry is Artelo Biosciences in?

Artelo Biosciences is in the Biotechnology industry

What country is Artelo Biosciences from?

Artelo Biosciences is headquartered in United States

When did Artelo Biosciences go public?

Artelo Biosciences initial public offering (IPO) was on 21 June 2019

What is Artelo Biosciences website?

https://www.artelobio.com

Is Artelo Biosciences in the S&P 500?

No, Artelo Biosciences is not included in the S&P 500 index

Is Artelo Biosciences in the NASDAQ 100?

No, Artelo Biosciences is not included in the NASDAQ 100 index

Is Artelo Biosciences in the Dow Jones?

No, Artelo Biosciences is not included in the Dow Jones index

When was Artelo Biosciences the previous earnings report?

No data

When does Artelo Biosciences earnings report?

Next earnings report date is not announced yet